Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

5.1K
The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.1K
Abnormal Proliferation02:23

Abnormal Proliferation

4.0K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.0K
Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal01:22

Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal

1.8K
Erythropoietin-producing hepatocellular carcinoma receptor (Eph) and its ligand, Eph receptor-interacting protein (Ephrin) were first discovered in the human carcinoma cell line, hence the name. Ephrin-Eph interaction guides cells to reach their appropriate location in adult tissues. They also play an essential role in the immune system by helping in immune cell migration, adhesion, and activation. Based on their structure and function, Eph is divided into two classes — EphA and EphB.
1.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Unraveling Signaling Pathways in Immune Microenvironment Crosstalk to Overcome Immunotherapy Resistance in Colorectal Cancer.

Human mutation·2026
Same author

APOBEC3C Suppresses Prostate Cancer by Regulating Key Molecules Involved in Cellular Inflammation, Cell Cycle Arrest, and DNA Damage Response.

Cancers·2026
Same author

Extracellular Vesicle-Mediated O-GlcNAcase Transfer Drives Neuronal Necroptosis to Facilitate Gallbladder Cancer Perineural Invasion.

Cancer research·2025
Same author

Common immunological and prognostic features of lung and bladder cancer via smoking-related genes: PRR11 gene as potential immunotherapeutic target.

Journal of cellular and molecular medicine·2024
Same author

Unveiling the role of YARS1 in bladder cancer: A prognostic biomarker and therapeutic target.

Journal of cellular and molecular medicine·2024
Same author

A Novel Nomogram Combined the Aggregate Index of Systemic Inflammation and PIRADS Score to Predict the Risk of Clinically Significant Prostate Cancer.

BioMed research international·2023

Related Experiment Video

Updated: Apr 23, 2026

Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies
07:47

Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies

Published on: September 15, 2023

2.2K

HSPB6: A Potential Prognostic Biomarker, Inhibiting the Epithelial-Mesenchymal Transition (EMT) Process Through the

Jian-She Wang1,2, Yi-Fan Qiu3, Lu Zhang2

  • 1Department of Urology, Yinfeng (Jinan) Hospital, Jinan, Shandong, China.

Human Mutation
|April 22, 2026
PubMed
Summary

Heat Shock Protein Beta-6 (HSPB6) overexpression inhibits bladder cancer (BC) cell proliferation and epithelial-mesenchymal transition (EMT). HSPB6 shows potential as a diagnostic marker and therapeutic target for BC.

Keywords:
HSPB6biomarkerbladder cancerepithelial–mesenchymal transitionprognostic model

More Related Videos

Induction and Analysis of Epithelial to Mesenchymal Transition
10:37

Induction and Analysis of Epithelial to Mesenchymal Transition

Published on: August 27, 2013

38.0K
Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells
06:54

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Published on: October 27, 2020

13.0K

Related Experiment Videos

Last Updated: Apr 23, 2026

Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies
07:47

Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies

Published on: September 15, 2023

2.2K
Induction and Analysis of Epithelial to Mesenchymal Transition
10:37

Induction and Analysis of Epithelial to Mesenchymal Transition

Published on: August 27, 2013

38.0K
Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells
06:54

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Published on: October 27, 2020

13.0K

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Bladder cancer (BC) presents a significant global health challenge with limited effective treatments.
  • Current BC therapies often fail, leading to disease progression and patient mortality.

Purpose of the Study:

  • To investigate the role of Heat Shock Protein Beta-6 (HSPB6) in bladder cancer.
  • To identify HSPB6 as a prognostic factor and potential therapeutic target for BC.

Main Methods:

  • Correlation analysis of HSPB6 expression with clinical grades and stages in BC patients.
  • Enrichment analysis to determine HSPB6's association with extracellular matrix components.
  • Experimental validation of HSPB6's effect on BC cell proliferation and signaling pathways (PI3K/Akt, EMT).
  • Development of a prognostic risk model using specific genes (DDR2, DPYSL3, MFAP5, PDGFRB, SPOCD1) and immunological status.

Main Results:

  • Elevated HSPB6 expression is an independent prognostic risk factor for BC, correlating with higher clinical grades and stages.
  • HSPB6 overexpression inhibits T24 bladder cancer cell proliferation.
  • HSPB6 inhibits the PI3K/Akt signaling pathway, leading to the suppression of epithelial-mesenchymal transition (EMT).
  • A prognostic risk model incorporating DDR2, DPYSL3, MFAP5, PDGFRB, and SPOCD1 accurately predicts patient outcomes based on immunological status.

Conclusions:

  • HSPB6 overexpression restrains BC cell proliferation and inhibits EMT.
  • HSPB6 holds promise as a diagnostic marker and therapeutic target for bladder cancer.
  • The developed prognostic model aids in predicting BC patient outcomes.